Skip to main content
AMCP Nexus 2025 Posters Main banner

    Real World Evidence

    E-Poster Available

    (343) Research Topics Addressed in Observational Claims-based Studies in Pharmacy

    Wednesday, October 29, 2025

      Presenter(s)

    • Veronika Hicks, n/a

      Pharmacy Student
      Western New England University
      Abingdon, Maryland, United States

      • Primary Author(s)

    • Veronika Hicks, n/a

      Pharmacy Student
      Western New England University
      Abingdon, Maryland, United States

      • Co-Author(s)

    • Natalia Shcherbakova, PhD

      Associate Professor of Pharmacoeconomics
      Western New England University
      Springfield, Massachusetts, United States


    Background:     : Pharmacy and medical claims data offer diverse opportunities for health outcomes, pharmacoepidemiology, and pharmacy practice researchers to perform real-world observational studies.

    Objective: : This study aims 1) to assess types of claims data used in articles published in 3 key pharmacy journals 2) to classify articles by research question answered.

    Methods: : We identified all articles published between January 2020 and December 2024 in the Journal of the American Pharmacist Association (JAPhA), Research in Social and Administrative Pharmacy (RSAP), and Pharmacoepidemiology and Drug Safety (PDS) that reported use of pharmacy and medical claims data. Articles were assessed by 2 reviewers and a decision for inclusion was made via consensus. Included articles were analyzed to identify the claims source, the research question addressed, the country of origin, and the sample size.

    Results: : A total of 314 articles published between 2020-2024 used claims as the data source. Claims sources were private (n=9), private and public (n=79), and public health insurance (n=226) data. The studies addressed the following research questions: methodology (n=68), healthcare services utilization patterns (n=56), adverse events (n=47), prescribing patterns (n=29), health outcomes (n=21), health policy impact (n=18), sociodemographic factors (n=16), adherence (n=14), drug safety (n=11), co-prescribing patterns (n=10), drug safety in pregnancy (n=9), costs (n=6), pharmacy services (n=3), drug effectiveness (n=2), other (n=2), drug information (n=1), drug manufacturing (n=1), The studies’ sample size varied between 158 and 73,300,000 patients. These claims-based studies originated from 35 countries with the top one being the U.S. (n=139), followed by Denmark (n=23), France (n=13) and Canada (n=14).

    Conclusions: : Claims provide readily available data to answer a wide variety of research questions in real-world evidence studies.

    Sponsorship:: None